NYSE:ABBVBiotechs
Positive Rinvoq Trial and Strong Earnings Might Change The Case For Investing In AbbVie (ABBV)
Earlier this month, AbbVie announced positive Phase 3 trial results for Rinvoq in severe alopecia areata, demonstrating significantly higher rates of scalp hair coverage compared to placebo, and reported quarterly earnings that exceeded analyst expectations, driven by key product performance and raised annual guidance.
This clinical trial milestone and earnings momentum highlight AbbVie's ability to advance its immunology pipeline while continuing to recover from Humira's loss of...